[ad_1] The U.S. Food and Drug Administration’s accelerated approval program aims to give patients early access to promising drugs. But how often do these medications actually improve or prolong patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such benefits within …
Read More »
[ad_1] WASHINGTON– The maker of a Lou Gehrig’s disease drug that recently failed in a large study said Thursday that it is withdrawing the drug from the market, acknowledging that it did not help patients with the deadly neurological disease. Amylyx Pharmaceuticals announced it will voluntarily stop sales and marketing …
Read More »
[ad_1] During the course, King was part of a team charged with identifying research that could be conducted in space with the greatest potential impact on humanity. His team came up with the concept of crystallizing drugs in microgravity. There was data amassed on the International Space Station that hinted …
Read More »
[ad_1] WASHINGTON– The maker of a hotly debated drug for Lou Gehrig’s disease said Friday that its therapy did not help patients in a large follow-up study, but stopped short of committing to an earlier promise to pull the drug from the U.S. market. The Food and Drug Administration approved …
Read More »
[ad_1] INDIANAPOLIS — Federal regulators postponed a decision on approving an Eli Lilly Alzheimer’s drug by making an unusual request for outside advisers to review the treatment. Lilly expected the Food and Drug Administration to decide on approval of donanemab by the end of the month. But the drugmaker said …
Read More »